Cipla LtdNSE: CIPLA

Press Release Sep 25 2020

· Issued by Cipla Ltd

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Cipla Ltd has issued a press release announcing the receipt of final approval for its generic version of Biogen IDEC Inc.’s Tecfidera® from the US FDA. The approved product includes Dimethyl Fumarate DR Capsules in various dosages and is indicated for treating relapsing forms of multiple sclerosis. Cipla's generic version is now available for shipping and will include Co-Pay Assistance for patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Cipla Limited has informed the Exchange regarding a press release dated September 25, 2020, titled "Cipla receives final approval for generic version of Biogen IDEC Inc. s Tecfidera�� (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack)".

Cipla Ltd on 6ix

Earlier from Cipla

Later from Cipla

All Cipla news releases